Ishan Capila, PhD

He has co-founded 2 companies and has been advising startup companies as a consultant for the last 3 years. He has been the VP of Research and Development at Celltas Bio and Vavotar Life Sciences. Prior to this he served as Senior Director, Research and Data Analytics at Momenta Pharmaceuticals. At Momenta, he played a key scientific role in the ANDA filing and approval of two complex generic drugs in the US (Enoxaparin Sodium and Glatopa®).

Dr. Capila has been involved in developing novel products from early target discovery, lead candidate development, and through IND filing for cardiovascular, autoimmune, infectious disease, and oncology applications. He is experienced with numerous regulatory filings and interactions with FDA.

Dr. Capila joined the Voltron team as a consultant, leading their CMC operations in June 2022.

Earlier in his career Dr. Capila was a postdoctoral associate at the Massachusetts Institute of Technology (MIT). Before joining MIT, he was a Research Fellow at Harvard Medical School and Boston Children’s Hospital, studying the biology of heparan sulfate proteoglycans. Dr. Capila has a Ph.D. in Medicinal and Natural Products Chemistry from the University of Iowa. He has authored two book chapters, and over 50 technical and review articles. He is also the named inventor / co-inventor on more than 30 patents and patent applications in the US and Europe.